Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biology-driven neoadjuvant trastuzumab deruxtecan trial for HER2-positive breast cancer
NL-OMON61453Phase 2Not yet recruiting
- Sponsor
- Karolinska University Hospital
- Start
- May 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan, ribociclib, trastuzumab, pertuzumab, docetaxel and 1 more in breast cancer (4 arms), sponsored by Karolinska University Hospital. Primary endpoint: Pathologic complete response in molecularly HER2-enriched population. Planned start May 2023; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON61453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61453.